193 results on '"Brooks, B. R."'
Search Results
2. Subcortical reorganization in amyotrophic lateral sclerosis
3. AN ADAPTIVE SAFETY AND DOSE FINDING STUDY OF FAMPRIDINE-SR IN EARLY AMYTROPHIC LATERAL SCLEROSIS
4. CD8 and CD4 T cell-mediated polymyositis complicating the HTLV-1 associated myelopathy. Quantitative evaluation of corticosteroid treatment
5. Normal modes for large molecules with arbitrary link constraints in the mobile block Hessian approach.
6. Theoretical study of the ground-state vibrations of the linear polyenes.
7. Transition from B to Z DNA: Contribution of Internal Fluctuations to the Configurational Entropy Difference
8. 48th ENMC international workshop: Drug trials and clinical research in ALS 12-14 January 1997, Naarden, the Netherlands
9. PATHOGENESIS OF MURINE RETROVIRUS INDUCED SPONGIOFORM ENCEPHALOMYELOPATHY
10. MURINE NEUROTROPIC RETROVIRUS: INFECTION OF DISSOCIATED MOUSE EMBRYONIC CENTRAL NERVOUS SYSTEM CULTURES IN VITRO
11. CHARMM: The biomolecular simulation program.
12. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
13. Failure to detect enterovirus in the spinal cord of ALS patients using a sensitive RT-PCR method.
14. Dissociation between mechanical and myoelectrical manifestation of muscle fatigue in amyotrophic lateral sclerosis.
15. Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: Beta-2 adrenergic agonists.
16. The ALS patient care database: goals, design, and early results. ALS C.A.R.E. Study Group.
17. Models of δ-hemolysin membrane channels and crystal structures.
18. SPONGIFORM POLIOENCEPHALOMYELOPATHY CAUSED BY A MURINE RETROVIRUS. II. ULTRASTRUCTURAL LOCALIZATION OF VIRUS REPLICATION AND SPONGIFORM CHANGES IN THE CENTRAL NERVOUS SYSTEM.
19. Slow Viral Infections.
20. Relationships between speech intelligibility and the slope of second-formant transitions in dysarthric subjects.
21. Home ventilation for amyotrophic lateral sclerosis patients.
22. Linkage analysis in familial amyotrophic lateral sclerosis.
23. Physiologic and metabolic response to progressive and prolonged exercise in amyotrophic lateral sclerosis.
24. Norepinephrine and gamma-aminobutyric acid in amyotrophic lateral sclerosis.
25. Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood cerebrospinal fluid barrier for norepinephrine.
26. Hypoglossal, trigeminal, and facial motoneuron involvement in amyotrophic lateral sclerosis.
27. Spinal seizures following intravenous contrast in a patients with a cord AVM.
28. Changes in Substance P (Sub P), 5-hydroxytryptamine (5-HT), and Thyrotropin-releasing Hormone (TRH)-like Immunoreactivity (LI) in Spinal Cord During Murine Neurotropic Retrovirus-induced Motor Neuron Degeneration.
29. Quantitative and Qualitative Differences in TRH Metabolism in NIH:N Mouse Brain and Spinal Cord.
30. Cerebrospinal Fluid Thyrotropin-releasing Hormone (TRH) Concentration Kinetics After Intravenous Thyrotropin-releasing Hormone Administration.
31. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].
32. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.
33. 'Mineral transporter' therapy for multiple sclerosis complicated by bacterial endocarditis.
34. Erratum.
35. MURINE NEUROTROPIC RETROVIRUS.
36. Nonequilibrium Uptake Kinetics of 125I Thyrotropin-releasing Hormone (TRH) into Spinal Cord and Brain Following Intravenous, Intraperitoneal, or Subcutaneous Administration in NIH:N Mice.
37. Mobile Block Hessian Approach with Adjoined Blocks: An Efficient Approach for the Calculation of Frequencies in Macromolecules.
38. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.
39. Molecular modeling of nucleic acid structure.
40. Quantitative assessment of motor fatigue in amyotrophic lateral sclerosis.
41. Multiple tactile maps in the human cerebellum.
42. Molecular dynamics simulations of human rhinovirus and an antiviral compound.
43. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.
44. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
45. Synthesis of virus-specific high-mobility DNA after temperature upshift of SC-1 cells chronically infected with moloney murine leukemia virus mutant ts1.
46. Functional magnetic resonance imaging (fMRI) clinical studies in ALS--paradigms, problems and promises.
47. Versailles minimal dataset for diagnosis of ALS: a distillate of the 2nd Consensus Conference on accelerating the diagnosis of ALS. Versailles 2nd Consensus Conference participants.
48. Problems in shortening the time to confirmation of ALS diagnosis: lessons from the 1st Consensus Conference, Chicago, May 1998.
49. Risk factors in the early diagnosis of ALS: North American epidemiological studies. ALS CARE Study Group.
50. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.